Evolus Reports Q4 Earnings, Raises 2026 Revenue Guidance

Specialty pharma company sees continued growth in key products and expects profitability in 2026.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Evolus, a specialty pharmaceutical company focused on medical aesthetics, reported its fourth quarter 2025 earnings results on Tuesday. The company reported revenue of $90.3 million, slightly exceeding analyst estimates, though earnings per share missed expectations. Evolus also raised its full-year 2026 revenue guidance to $327 million to $337 million, above the previous Street consensus.

Why it matters

Evolus' results and guidance suggest the company is maintaining momentum with its flagship Jeuveau neurotoxin product, which reached around 14% U.S. market share, as well as progress with its Evolysse line of products. The company's path to profitability in 2026 is an important milestone, though it faces ongoing market and policy headwinds such as tariffs and new competitor launches.

The details

In the fourth quarter, Evolus reported revenue of $90.3 million, up 14% year-over-year and slightly above the $89.6 million expected by analysts. However, the company reported earnings per share of $0.00, missing the consensus estimate of $0.09. For the full year 2025, Evolus generated revenue of $297.2 million, up 12% from the prior year. Looking ahead, the company raised its 2026 revenue guidance to a range of $327 million to $337 million, above the previous Street consensus of around $316 million. Evolus also expects to achieve profitability on an adjusted EBITDA basis in 2026, with a goal of reaching 13-15% adjusted EBITDA margins by 2028.

  • Evolus reported its Q4 2025 earnings results on Tuesday, March 4, 2026.
  • The company expects to file for FDA approval of its Evolysse Sculpt product in Q4 2026 and plans a large sampling program for Q2 2026.

The players

Evolus

A specialty pharmaceutical company focused on medical aesthetics, headquartered in Newport Beach, California.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.